Lexaria Bioscience Corp Aktie News

Strategic Business Development Advisory Firm Engaged To Support New Business Development Activities Lexaria Awarded 4 New Patents KELOWNA, BC / ACCESS Newswire / October 9, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to provide the following strategic business update. For several years, Lexari...

Strategic Business Development Advisory Firm Engaged To Support   New Business Development Activities

Kelowna, British Columbia - September 29, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced  at-the-market under Nasdaq rules of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at...

KELOWNA, BC / ACCESS Newswire / September 29, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at a p...

Kelowna, British Columbia – TheNewswire - September 26, 2025 - Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at a purchase price of $1.50 per sha...

KELOWNA, BC / ACCESS Newswire / September 26, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has entered into a definitive agreement for the purchase and sale of an aggregate of 2,666,667 shares of its common stock, par value $0.001 per share, at a purchase price of $1.50 per share in a re...

Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and Efficacy    Kelowna, British Columbia – September 19, 2025 – TheNewswire - Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “ Company ” or “ Lexaria ”), a global innovator in drug delivery platforms, is pleased to announce successful results from its fluorescently tagged semaglutide (“ FTS ”) rodent bi...

Enhanced Brain Biodistribution of GLP-1 Drugs May Be Related to Improvements in Safety and Efficacy KELOWNA, BC / ACCESS Newswire / September 19, 2025 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce successful results from its fluorescently tagged semaglutide ("FTS") rodent biodistribution...